Full-Time

Associate Director

Patient Recruitment & Retention

Confirmed live in the last 24 hours

Medpace, Inc.

Medpace, Inc.

1,001-5,000 employees

No salary listed

Senior, Expert

Cincinnati, OH, USA

Relocation assistance will be provided for applicable candidates.

Category
Human Resources
People & HR
Required Skills
Marketing
Requirements
  • Bachelor's degree and 8+ years of patient recruitment management experience
  • Extensive knowledge of marketing and advertising strategies related to patient recruitment
  • Successful ability to think strategically and participate in business development activities
  • Demonstrated ability to identifying, target, acquire, and manage multiple vendors
  • Extensive knowledge and demonstrated success in developing patient recruitment and retention strategies
  • Excellent diplomacy and organizational skills
Responsibilities
  • Oversees the partnerships with Clinical Trial Managers to develop patient recruitment and retention plan that drive the patient recruitment and retention
  • Manages a team of Patient Recruitment Coordinators and/or Managers
  • Collaborates with clinical operations team to review protocol feasibility and offer input on the appropriate recruitment and retention strategies
  • Supports the Business Development team in the bid defense process to present the patient recruitment focus of the proposal and represents the patient recruitment department at the Bid Defense
  • Supervises the Development and maintenance patient related metrics
  • Initiates marketing efforts with Information Design Group for study-specific material development
  • Identifies, targets, and furthers strategic partnerships with specialized vendors

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant revenue growth in Q4 2023 indicates strong market demand and effective strategies.
  • Recent investments by financial institutions reflect confidence in Medpace's growth potential.
  • Expansion of medical leadership team suggests increased focus on clinical research and development.

What critics are saying

  • Increased competition from Lantheus and others may pressure Medpace's market share.
  • New Cincinnati office construction could lead to higher operational costs and project delays.
  • Decreased net income margin in 2023 indicates challenges in maintaining profitability.

What makes Medpace, Inc. unique

  • Medpace's expansion in infectious diseases and vaccines shows strategic focus on high-demand sectors.
  • New leadership in respiratory and women's health enhances Medpace's expertise and service offerings.
  • Commitment to infrastructure growth with new Cincinnati office supports future operational efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Unlimited Paid Time Off

Competitive Compensation and Benefits Package

Employee Health and Wellness Initiatives

Hybrid Work Options

Structured Career Paths with Opportunities for Professional Growth

Company News

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

Stock Titan
Aug 15th, 2024
Skanska builds new office building in Cincinnati, Ohio, USA, for USD 164M, about SEK 1.7 billion

STOCKHOLM, Aug. 15, 2024 /PRNewswire/ - Skanska has signed a contract with Medpace, a clinical research company, for the construction of a new office building in Cincinnati, Ohio, USA.

MarketBeat
Apr 8th, 2024
First National Bank of Hutchinson Invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

First National Bank of Hutchinson invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP).

PharmiWeb
Feb 13th, 2024
Medpace Holdings, Inc. Reports Fourth Quarter And Full Year 2023 Results

Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%.Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x.Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter of 2023 and 2022, respectively.EBITDA was $95.8 million for the fourth quarter of 2023, an increase of 19.2% from EBITDA of $80.4 million for the comparable prior-year period, resulting in an EBITDA margin of 19.2%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Results

MarketBeat
Feb 2nd, 2024
Hussman Strategic Advisors Inc. Invests $1.02 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Hussman Strategic Advisors Inc. invests $1.02 million in Medpace Holdings, Inc. (NASDAQ:MEDP).